Cuba will commence the third phase of the clinical trial of two vaccines against the new coronavirus next week and will be able to convert into the first country of Latin America to consume an immunosuppressed trial and national manufacture, announcing directives and scientists.
Given the good results of the first two phases and at the same time the industrial scale is producing the most advanced vacuum of them, the Soberana 02, the Cuba cual tend the production capacity 110 million dose in 2021 to the other summer number not determined by the lame Abdalá.
“The Cuban tax has ten very effective vacancies, the second tax is that its vacancies are very secure, the third is that it does not have the limit of the dose number that can be applied, you can have to immunize in six months if you need it, is for the new mutations ”, says a group of periodists the director of the Institut Finlay, Vicente Vérez, during a recording of the production plants.
Cuba also has other vacancies in the studio, Mambisa and Soberana 01. No one working with live viruses is from parties, as it is even more secure to allow for various inoculations and a holiday without strict restrictions.
The Soberana 01 and 02 are based on the processing of superior mammalian cells and carried out by the Finlay and the Center for Molecular Immunology (CIM). Abdalá and Mambisa -of intranasal application- have part of the processes processed by the Center for Genetic Engineering and Biotechnology (CIGB), indicating the experts.
“Their products – the Abdalá and the Mambisa by a lad and the Sober on the other – with different technologies for a different proposal”, explained Jorge Luis Vega, the Associated Press’ director of production at the CIGB.
Cuba has an important state-of-the-art polo formed in the 80s that invests and produces many of the medicines needed for its internal market, including 80% of the vacancies of its national health program that are free.
The recommendation:
Experts indicate that the urgency of the new coronavirus’s propagation of the island’s plan is based on analyzing a set of candidates each year.
“There was a pandemic situation where there were advances with various strategies,” said Marta Ayala, director of the CIGB, saying that the general investigation into a vacancy could take up to 10 years and that the process would take place in months.
The scientists indicate that the results of the first of the phases -which are focused on the safety of the product- were published in articles on special pages in order for them to be revised as the establishment of the International Community of Specialists 19 the COV.
The third phase of the Soberana and the Abdalá will begin between March 3 and 8, informs Eduardo Ojito, director of the CIM, that it means that people in the island of Comenzar will receive a dose.
During this phase it will also be analyzed if it is necessary to apply a third dose to reactivate the vaccine or if it is possible to combine Soberana 02 with another drug to obtain a more large dose.
Eduardo Martínez, Director of BioCubafarma, states that the Cuban drug trade, recognizing that in the world it has appetite for vacancies and the island is negotiated with some countries, but more details are available.
Cuba has been experiencing a COVID-19 strike since November, when commercial avenues were renewed, with the government applying new Islamic means. Hasta now in the island has produced more than 47,000 cases of the new coronavirus and about 400 cases.